Rose BioSolutions Welcomes Dr. Thomas VanCott as Leader of HemaCare: Advancing Cell Therapy Services
Rose BioSolutions has announced the appointment of Dr. Thomas VanCott, Ph.D., as the head of HemaCare, its dedicated Cell Solutions initiative aimed at enhancing cell therapy services. With over 30 years of experience in the realms of cell therapy and biologics development, Dr. VanCott's extensive background is anticipated to play a pivotal role in advancing Rose Bio's offerings and capabilities.
Prior to this, Dr. VanCott was the CEO of Excellos, a contract development and manufacturing organization (CDMO) specializing in cell therapies. His leadership experience in navigating the operational complexities of manufacturing and developing advanced therapies positions him well to oversee HemaCare's business operations at Rose Bio. In his new role, Dr. VanCott will work closely with clients to ensure they have reliable access to the high-quality cellular materials needed for complex and evolving gene therapy programs.
"As the landscape of cell and gene therapy continues to evolve, our clients' needs are becoming increasingly complex. The demand for high-quality cellular materials is rising significantly," commented Dr. VanCott. He emphasized that HemaCare's unique positioning within the industry makes it well-suited to cater to these burgeoning requirements. He also noted that merging top-tier quality with scientific expertise allows the platform to support some of the most demanding projects in the field.
Dave Kreter, Managing Director and Head of Healthcare Investments at GI Partners, highlighted the importance of strong leadership within Rose Bio. He stated, "The construction of a world-class organization requires leaders who not only possess scientific knowledge but also a clear understanding of client needs." Kreter expressed excitement about Dr. VanCott joining the Rose Bio team and believes his operational know-how will further solidify their capacity to provide leading cell solutions.
This leadership transition at Rose Bio follows its recent establishment as an independent entity, after GI Partners acquired the CDMO and Cell Solutions branches from Charles River Laboratories back in May 2026. With this newfound independence, Rose Bio is now dedicated to fostering innovation and expanding its portfolio of services while focusing on long-term strategies to offer comprehensive solutions across the cell and gene therapy landscape.
Alongside Dr. VanCott's appointment, Rose Bio also revealed plans to rebrand its Cell Solutions business as HemaCare, affirming its commitment to aligning its identity with its mission to deliver superior cell therapies.
Rose BioSolutions operates from several key locations, including Rockville, Maryland; Memphis, Tennessee; Northridge, California; and Keele, United Kingdom. The company is committed to being at the forefront of the cell and gene therapy sectors by providing development and manufacturing capabilities that span across plasmid DNA, viral vectors, and a variety of cell therapies.
This strategic move to appoint Dr. VanCott reflects Rose Bio's commitment to not only expand its operational capacity but also to ensure that it remains a vital player in meeting the growing demands of the life sciences industry. For more news and updates, visit rosebiosolutions.com.
Prior to this, Dr. VanCott was the CEO of Excellos, a contract development and manufacturing organization (CDMO) specializing in cell therapies. His leadership experience in navigating the operational complexities of manufacturing and developing advanced therapies positions him well to oversee HemaCare's business operations at Rose Bio. In his new role, Dr. VanCott will work closely with clients to ensure they have reliable access to the high-quality cellular materials needed for complex and evolving gene therapy programs.
"As the landscape of cell and gene therapy continues to evolve, our clients' needs are becoming increasingly complex. The demand for high-quality cellular materials is rising significantly," commented Dr. VanCott. He emphasized that HemaCare's unique positioning within the industry makes it well-suited to cater to these burgeoning requirements. He also noted that merging top-tier quality with scientific expertise allows the platform to support some of the most demanding projects in the field.
Dave Kreter, Managing Director and Head of Healthcare Investments at GI Partners, highlighted the importance of strong leadership within Rose Bio. He stated, "The construction of a world-class organization requires leaders who not only possess scientific knowledge but also a clear understanding of client needs." Kreter expressed excitement about Dr. VanCott joining the Rose Bio team and believes his operational know-how will further solidify their capacity to provide leading cell solutions.
This leadership transition at Rose Bio follows its recent establishment as an independent entity, after GI Partners acquired the CDMO and Cell Solutions branches from Charles River Laboratories back in May 2026. With this newfound independence, Rose Bio is now dedicated to fostering innovation and expanding its portfolio of services while focusing on long-term strategies to offer comprehensive solutions across the cell and gene therapy landscape.
Alongside Dr. VanCott's appointment, Rose Bio also revealed plans to rebrand its Cell Solutions business as HemaCare, affirming its commitment to aligning its identity with its mission to deliver superior cell therapies.
Rose BioSolutions operates from several key locations, including Rockville, Maryland; Memphis, Tennessee; Northridge, California; and Keele, United Kingdom. The company is committed to being at the forefront of the cell and gene therapy sectors by providing development and manufacturing capabilities that span across plasmid DNA, viral vectors, and a variety of cell therapies.
This strategic move to appoint Dr. VanCott reflects Rose Bio's commitment to not only expand its operational capacity but also to ensure that it remains a vital player in meeting the growing demands of the life sciences industry. For more news and updates, visit rosebiosolutions.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.